When it comes to har­ness­ing da­ta for health­care and the life sci­ences, a rich in­fra­struc­ture of ex­pan­sive da­ta col­lect­ed and mea­sured with the right tools are es­sen­tial to un­cov­er new in­sights and ad­vance new prod­ucts. And to build that, you need ac­cess to di­verse tal­ents backed by a pa­tient in­vestor.

Jim Tanan­baum

Just ask Vik Ba­jaj. The for­mer UC Berke­ley re­searcher first left acad­e­mia for Ver­i­ly, Google’s for­ay in­to life sci­ences, where he saw the meth­ods of mar­ry­ing com­pu­ta­tion and bi­ol­o­gy were near­ing ma­tu­ri­ty. Af­ter a few years as CSO there he moved on to Grail work­ing to­wards the ear­ly de­tec­tion of can­cer — an­oth­er da­ta in­ten­sive en­deav­or — be­fore land­ing his cur­rent role as man­ag­ing di­rec­tor of Fore­site Cap­i­tal.

Yet in spite of all the progress he’s seen and helped prop­a­gate, it’s not quite there yet. There is still a gap be­tween what’s cur­rent­ly avail­able and what he sees as a trans­for­ma­tion in health­care en­abled by the in­for­ma­tion rev­o­lu­tion.

“Re­al­ly what we per­ceive — and ob­vi­ous­ly I’m not alone in stat­ing this — is that there is an eco­nom­ic cri­sis in our health­care sys­tem where we are spend­ing so much of our na­tion­al prod­uct on health­care and yet we have out­comes that are ac­tu­al­ly in de­cline in many pop­u­la­tions,” Ba­jaj told End­points News. “And we think that there are many ways to make that in­dus­try more ef­fi­cient and more re­spon­sive to the needs of its pa­tients, but ob­vi­ous­ly this idea of us­ing da­ta sci­ence, the pow­er of mea­sure­ments, of un­der­stand­ing of ex­per­i­ments is fun­da­men­tal to gen­er­at­ing re­li­able ev­i­dence that will solve some of these large health­care prob­lems.”

The no­tion is what spurred him and Fore­site CEO Jim Tanan­baum to launch Fore­site Labs, an en­tre­pre­neur­ial in­cu­ba­tor de­signed to nur­ture some of the foun­da­tion­al com­pa­nies at the nexus of da­ta sci­ence and health­care.

Fore­site Labs re­moves three of the biggest bar­ri­ers for star­tups in this space, ac­cord­ing to Ba­jaj: It of­fers a pool of pub­lic and pro­pri­etary datasets, which would be ex­pen­sive for any one com­pa­ny to gen­er­ate; an analy­sis plat­form con­sist­ing of the lead­ing tools to aid with clin­i­cal ap­pli­ca­tion of da­ta; as well as a sea­soned team of 20-plus — be­tween the Boston and San Fran­cis­co of­fices — to of­fer sci­en­tif­ic, tech­ni­cal and busi­ness sup­port. As part of that, they al­so hook com­pa­nies up with part­ners for re­sources such as lab space.

Cor­re­spond­ing­ly, he sees three types of ven­tures that would ben­e­fit the most from their in­cu­ba­tion — and that they would be most in­ter­est­ed in.

The first in­volves ther­a­peu­tic op­por­tu­ni­ties cen­tered around func­tion­al ge­nomics; the sec­ond group build the in­fra­struc­ture need­ed for clin­i­cal de­vel­op­ment us­ing re­al-world ev­i­dence; the third cat­e­go­ry would look in­to per­son­al­ized health­care de­liv­ery based on in­di­vid­ual as­sess­ment of dis­ease risk.

Out­side of these high lev­el de­tails, though, he’s let­ting lit­tle else slip about what Fore­site Labs has been work­ing on over the past year. The cap­i­tal Fore­site has to de­ploy, the num­ber of ven­tures they would back at any one time, the ca­pa­bil­i­ties they are con­sid­er­ing adding — these are all stay­ing un­der wraps.

One thing we know, though, is that Fore­site has plen­ty of fire­pow­er and pa­tience to seed com­pa­nies where they see po­ten­tial. Last May the firm closed its fourth fund at a record $668 mil­lion and vowed to beef up their ma­chine learn­ing chops to en­able bet­ter in­vest­ment de­ci­sions.

“We’re get­ting in­to this area where we be­lieve through long ex­pe­ri­ence has tremen­dous po­ten­tial,” he said. “But it’s a po­ten­tial that will be re­al­ized rough­ly over the next decade. […] That means that we’re go­ing to be ini­tial­ly very mea­sured in what we do, and very de­lib­er­ate in launch­ing a few high qual­i­ty com­pa­nies with­out putting num­bers or tar­gets on it.”

The team of ex­perts they’ve re­cruit­ed to Fore­site Labs, he added, should prove to be the great­est as­set over the long run. They in­clude:

• Alex Block­er, head of da­ta sci­ence (for­mer­ly of Grail and Ver­i­ly)
• Rick Dewey, head of ge­nomics dis­cov­ery (for­mer­ly of the Re­gen­eron Ge­net­ics Cen­ter)
• Damien Soghoian, head of op­er­a­tions and strat­e­gy (for­mer­ly of Ver­i­ly)
• Paul Da Sil­va Jar­dine, head of drug dis­cov­ery (for­mer­ly of Pfiz­er)

On top of that, he’s as­sem­bled a star-stud­ded sci­en­tif­ic ad­vi­so­ry board fea­tur­ing Math­ai Mam­men of J&J, Pao­la Ar­lot­ta of Har­vard, Eu­an Ash­ley of Stan­ford, Calum MacRae of Brigham and Women’s Hos­pi­tal, Steve Finkbein­er of Glad­stone, Jeff Hu­ber and Alex Ar­a­va­nis of Grail, as well as Rus­lan Medzhi­tov of the Howard Hugh­es Med­ical In­sti­tute.

“Ob­vi­ous­ly it will be an area that will be much big­ger than what Fore­site Labs does, but I think that we are a lit­tle bit ahead and so poised to have a huge in­flu­ence over the trans­for­ma­tion,” Ba­jaj said.

What’s Biohaven without its CGRP portfolio? That’s what CEO Vlad Coric is tasked with deciding as he maps out the “New Biohaven” post-Pfizer takeover.

Pfizer officially scooped up Biohaven’s CGRP assets on Monday, including blockbuster migraine drug Nurtec and the investigational zavegepant, for $11.6 billion. As a result, Coric spun the broader pipeline into an independent company on Tuesday — with the same R&D team behind Nurtec but about 1,000 fewer staffers and a renewed focus on neuroscience and rare disease.

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson will be doubling its investment in its New Jersey manufacturing center and will be investing a total of $500 million.

With an eye on their BCMA-directed CAR-T therapy Carvykti (cilta-cel), approved in February as a fifth-line treatment for multiple myeloma, Legend CEO Ying Huang said that the ramp-up in production and the decision to manufacture its own lentiviral vectors — currently in shortage worldwide — means they won’t have to deal with that shortage.

Kite Pharma just got FDA approval to kick off operations at a new manufacturing campus.

The cancer-focused, CAR-T cell therapy player made the announcement Monday, saying that the federal regulatory agency gave the green light to Kite’s 100,000 square-foot, retroviral vector manufacturing facility in Oceanside, CA.

Kite’s global head of technical operations Chris McDonald tells Endpoints News that the facility has been in the works for about four years, after Kite teamed up with its parent company Gilead. Gilead acquired Kite Pharma for just shy of $12 billion in 2017.